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Abstract Both cachexia and sarcopenia are associated with
muscle wasting, although cachexia may also involve other
tissues. Muscle wasting is encountered in the advanced stages
of many chronic illnesses. Several ongoing pre-clinical
and clinical studies are expected to ameliorate this clinical
problem. This article highlights the pre-clinical and clinical
studies in the field of wasting disorders that were presented at
the 6th Cachexia Conference in Milan, Italy, in December
2011. Effective treatments are urgently needed in order to
improve the patients’survival and quality of life. We describe
ongoing research into muscle proteolytic pathways and the
principal actors in skeletal muscle wasting. Novel therapeutic
approaches include interleukin-6 such as receptor antibody
tocilizumab, interleukin-1 receptor antagonist such as IP
1510 or selective androgen receptor modulators such as eno-
bosarm and LGD-4033. Other candidates embraced the ana-
bolic/catabolic transformingagent MT-102,naturally occurring
peptide hormones such as ghrelin and synthetic orally active
ghrelin receptor agonist anamorelin or the erythropoietin ana-
logues ARA284 and ARA286.
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